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1 Introduction and Aim of the Project 
The practice of sport is predominant in our society and it plays an important international 
role in the development not only of physical aspects but also of psychological skills. 
Unfortunately, some disregard the ideal of fair play and the principle of winning at all costs 
became dominant. The demand for ever higher physical performances and intensive 
training and competition, drive athletes to optimize nutrition, including the use of dietary 
supplements, in the belief of obtaining an advantage in competition by maximizing their 
performances while remaining healthy. Unfortunately, the lack of analytical control on 
dietary supplements can be the cause, in the worse but not only case, of possible risks for 
the health of the athletes. Indeed, were reported several cases of contamination of 
supplements with banned substances and presence of substances not listed or incorrectly 
listed on the label [1-17]. Furthermore, athletes' interest in a ‘natural alternative’ to improve 
muscular growth and, consequently, to enhance performances, is progressively increasing 
[18]. In this scenario, ecdysterone, a steroid hormone naturally occurring in plants and 
invertebrates, has been investigated since a large number of products containing 
ecdysterone are easily available via internet and there are many rumors on ecdysterone 
misuse by athletes. Ecdysterone is promoted as a ‘natural steroid’ capable of increasing 
strength and muscle mass as well as having anabolic effects.  
Consequently, this suggests that supplements containing ecdysterone may be used by 
athletes during training and competition to circumvent the anti-doping test since they are 
not yet included in the World Anti-Doping Agency’s (WADA) list of banned substances and 
methods. Only a few scientific studies are available to demonstrate the performance-
enhancing effect of ecdysterone and little is known about its metabolism. 
Thus, this project aims to investigate the effects of a long-term administration of 
ecdysterone containing dietary supplement in humans, to evaluate its efficacy in 
enhancement of sports performance during resistance training.  
Furthermore, this study is designed to develop sensitive and specific analytical methods for 
the unambiguous identification and quantitation of ecdysterone in natural preparations and 
in human biological fluids (urine and serum). A complete anti-doping screening examination 
of supplements and urines was carried out to exclude underlying effects from potential cross 
contamination. 
To trace back an administration of ecdysterone from urine samples, its analytical properties 
have been investigated in order to assess its integration into initial testing procedures (ITP) 
in doping control laboratories for monitoring the prevalence in elite sports.  
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2 Background 
2.1 Ecdysteroids: Characteristics, Occurrence in plants, 
Pharmacological and Anabolic effects 
Firstly reported in the mid-1960s studies of ecdysteroids began. A Japanese group, while 
researching anticancer substances, isolated ecdysteroids from a plant source [19, 20]. 
Ecdysteroids belong to a group of polyhydroxylated steroids, natural hormones of 
arthropods, responsible for moulting and metamorphosis, as the term ecdysis from Ancient 
Greek ἐκδύω (ekduo, “take it off”), indicates [19]. In plants, they operate as protective agents 
against predatory insects [21].  
The structure of the majority of ecdysteroids is based on C27 cholest-7-en-6-one backbone 
and cholesterol is considered the direct precursor. Indeed, following steps of their 
biosynthesis include conversion of cholesterol, (dehydrogenation to 7-dehydrocholesterol), 
further molecular modifications, and, especially, hydroxylation at various carbon atoms [22]. 
The most widely distributed ecdysteroid is ecdysterone (Figure 1) (also called β-ecdysone 
or 20-hydroxyecdysone) and is thought to be present in 147 plant species [19].  
Figure 1 Chemical structure of ecdysterone 
(2β,3β,14α,20β,22R,25-hexahydroxy-5β-cholest-7-en-6-one). 
One of the well-known sources of ecdysterone is Suma (common name: Brazilian Ginseng, 
Pfaffia glomerata) [21], in which it is mostly accumulated in roots in a percentage variation 
of 0.42 to 0.66% [23]. Spinach is another source of ecdysterone, but it contains only ca. 
0.005-0.08% of ecdysteroids (mostly ecdysterone) per fresh weight, depending on the time 
















hard to reach more than a hundred milligrams of ecdysterone per day [24]. Cyanotis 
arachnoidea, a plant native in China, is the richest source of ecdysterone (4-5%) [24].  
A wide range of effects such as stimulation of protein synthesis, changes in carbohydrate 
and lipid metabolism, increased cell immunity, adaptogenic, anti-diabetic, hepatoprotective 
and perhaps even anti-tumor effects [26-28] as well as growth-promoting and anabolic 
effects of ecdysterone in various animal species and in humans, have been reported [28-
45]. 
The anabolic effect of ecdysterone is mediated by activation of estrogen receptor beta 
(ERbeta) [29, 46, 47] and different studies reported the effect of ecdysterone to be even 
stronger than that of anabolic androgenic steroids (AAS) without sharing any of their 
classical side effects, such as virilization [28, 48, 49]. 
2.2 Dietary Supplements Containing Performance Enhancer 
2.2.1 Definition and regulation of dietary supplements  
The system of regulation of dietary supplements is not universal, and countries differ in their 
approach and practice [50]. 
United States of America 
Dietary supplements are defined in the United States of America (US) under the Dietary 
Supplement Health Education Act (DSHEA) of 1994, final version of which was published 
in 1997 [51], as certain products (other than tobacco) intended to supplement the diet that 
are not represented as conventional food. A dietary supplement can contain vitamins, 
minerals, amino acids, dietary substances, metabolites, constituents, herbs or other 
botanicals and their extracts or concentrates. Furthermore, it must be intended for ingestion 
in pill, capsule, tablet, powder or liquid form not represented for use as the sole item of a 
meal or diet and labelled as a ´dietary supplement’ [50, 52]. 
In the US, while the Food and Drug Administration (FDA) supervises the quality, the Federal 
Trade Commission (FTC) supervises the marketing and advertising of dietary supplements 
[53, 54]. According to the 1994 DSHEA [55], dietary supplements sold in the US, that are 
not intended to diagnose, treat, cure, or prevent any disease, do not need to be evaluated 
by the FDA before the product enters the market, unless they contain a new dietary 
ingredient [56]. A new dietary ingredient is defined as a dietary ingredient that was not 
marketed in the US before October 15th, 1994 [55-57]. In case of new ingredients, the 
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manufacturer is obliged to submit a 75-day pre-market notification to FDA, providing some 
evidence of the safety of the new ingredient but not being responsible for proving that a new 
ingredient is safe [58]. The FDA has, on the other hand, the authority to remove a product 
from the market if it exposes people to a risk of illness or injury [56, 57, 59]. 
If a manufacturer of a dietary supplement is making a claim about his product, before of the 
marketing of the product, the company is obliged to submit the claim to FDA within 30 days 
for approval [60].  
The 1994 version of the DSHEA contains a provision requiring the FDA to establish and 
enforce current Good Manufacturing Practices (cGMP) for dietary supplements [60]. It was 
not before June 2010 that new FDA rules were able to ensure compliance of dietary 
supplements with cGMP in order to manufacture them with “controls that result in a 
consistent product free of contamination, with accurate labelling” [50, 60]. Whereas the 
implementation of GMP requirements are specific for each manufacturer, it occurs a lack of 
uniformity across the industry. Even if FDA expressed explicitly, in the preamble of the GMP, 
that validated methods may be used for the uniformity in product quality (such as from 
Association of Official Agricultural Chemists (AOAC) International or United States 
Pharmacopeia (USP)), neither the validation of analytical methods is required nor the use 
of validated methods [56]. Consequently, supplements and food ingredients are similarly 
regulated and therefore they do not have strict labelling requirements and are not subject 
to the regulations applied to the pharmaceutical industry [59]. 
European Union and other countries 
In the European Union (EU), the Food Supplements Directive 2002/46/EC [61] defines food 
supplements as foodstuffs intended to supplement a normal diet and in which are 
concentrated sources of nutrients (vitamins and minerals) or other substances with a 
nutritional or physiological effect, alone or in combination. They are marketed in dose form, 
namely forms such as capsules, pastilles, tablets, pills and other similar forms, sachets of 
powder, ampoules of liquids, drop dispensing bottles, and other similar forms of liquids and 
powders designed to be taken in measured small unit quantities.  
The Directive 2002/46/EC establishes a list, also called “positive list”, of allowable vitamins 
and minerals (including requirements to the maximal and minimal amounts that can be 
used) and sets labeling requirement [50, 62]. However, the Directive 2002/46/EC only 
establishes rules for vitamins and minerals and not on the use of botanicals in food 
supplements [63]. In absence of centralized authorization procedure, the European 
Commission has stated that the use of botanicals and derived preparation in food 
supplements is requested to comply with the requirements for food established by the EU 
General Food Law as well as requirements for novel food [63]. Those requirements ban 
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products than are injurious to health and require authorization procedure, which includes 
safety assessment before they can be commercialized [63]. 
Behind this Directive, there is the European Food Safety Authority (EFSA), established from 
the European Parliament in the Regulation 2002/178/EC [64]. This Directive regulates 
principles and requirements of the Food Law, and scientific expert opinions are developed 
and interchanged, based on scientific evidence concerning the safety for human health of 
food supplements [62]. The EFSA introduced the term “novel food” which includes all food 
that has not been consumed to any significant degree in the EU before 15 May 1997 (when 
the first novel food legislation entered into force) [65]. Novel food can be innovative food 
produced with or without involving new technologies or production processes and cannot 
be included in the “positive list” before a pre-market authorization [65]. The EFSA is also 
responsible of performing analysis to approve possible health claims. Indeed, as it exists a 
positive list of substances, there is also a positive list of health claims permitted for use, as 
guarantee of reliability for consumers [50, 62].  
Anyway, botanical extracts are often used either in food supplements or in herbal medicinal 
products (HMPs), which are, unlike food supplements, under pre-market regulatory 
pathways established from the European Medicines Agency (EMA) [63]. Consequently, 
some products are marketed as food in certain EU Member States and as medicinal 
products in others, due to the lack of a harmonized authorization procedure [63].  
In other countries botanical supplements are regulated either as a special category of food 
(New Zealand, Japan, China and India) or as medicinal products (Canada, Australia [63]). 
In Table 1 is reported a summary of the relevant legislative instruments and information 
about the pre-market authorization of botanical food, provided and adapted from [63].  
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Table 1 Summary of relevant legislative instruments and requirements for premarketing 
authorization of botanical supplements in Australia, Canada, China, India, the European 
Union, New Zealand, Japan, and the USA, reported and adapted from [63]. 
Jurisdiction Legislative instrument Pre-marketing authorization 
required
Australia Therapeutic Goods Act Yes 
Canada Natural Health Products Regulations Yes 
China Food Safety Law of the People’s Republic of China and 
Measures for the Administration of Registration and Recording 
of Health Food 
Yes 
India Food Safety and Standards (Health Supplements, 
Nutraceuticals, Food for Special Dietary Use, Food for Special 
Medical Purpose, Functional Food and Novel Food) 
Regulations, 2016 
No 
European Union Directive 2002/46/EC of the European Parliament and of the 
Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements 
No, botanical ingredients 
meeting the definition of “novel 
food” must be authorized first 
Japan Food Sanitation Act (Act No. 233,1947) No – “Foods in general” 
Yes – “Foods with health 
claims” 
New Zealand Dietary Supplements Regulations 1985 Food Act 2014 No 
USA Dietary Supplement Health Education Act (DSHEA) 1994 No 
2.2.2 Use of dietary supplements in sport 
In the global market, the use of dietary supplements is estimated to reach almost $180 
billion by 2020 [66]. Their use within athletes is reported to range from 40 to 88% [50, 67]. 
Only in the US dietary supplements are used by 80% of the population [68]. The factors 
supporting the growth of this market are a higher interest of consumers to implement their 
diet, a high consumption by athletes, promotion strategies promoted by manufacturers and 
distributors, a liberal legal framework and a liberal distribution and sales regime [62]. 
Studies suggest that the use of supplements varies between different sports, increases with 
level of training or performance and with age, is strongly influenced by cultural customs and 
is higher in men than in women [59]. Female athletes are more likely to take supplements 
for health reasons or to implement their diet, while men to improve agility, strength and 
power, and to gain weight or muscles [50]. A study reported that the primary source of 
nutrition information are athletic trainers (40%), strength and conditioning coaches (24%) 
and dietitians (14%) [50, 69]. When a  high commitment to sport training among young 
people is associated to certain psychological disposition, such as insecurity and low self-
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esteem, it is more likely that they could benefit of the use of nutritional supplements [50, 
70]. 
Within the sport context, the interest to ‘alternative natural approaches’ has grown in the 
last decades and among those ‘natural’ supplements, ecdysteroids are definitely highly 
attractive together with phytoestrogens and vegetal sterols [18].  
Borrione et al. reported that for athletes, the possibility of increasing physical performances 
using natural products (erroneously considered harmless) is undoubtedly more attractive 
than having to rely on pharmacological approaches. Furthermore, the use of those natural 
therapeutic variants, not only is considered not doping but is also considered side-effect 
free [18].  
Ecdysteroids are widely marketed to athletes as dietary supplements advertising to increase 
strength and muscle mass during resistance training, to reduce fatigue and to ease recovery 
[48]. Ecdysterone has also been reported in the list of herbs most commonly used, 
nowadays, to enhance physical performances by providing or mimicking anabolic effects of 
testosterone (T) in humans because of their similarity of chemical structure [52].  
What most of the users do not know, is that for most of the supplements, the advertised 
ergogenic effects are not based on scientific evidence and, subsequently, they cannot be 
sure if their mid-term or long term consumption may constitute a risk for health [18]. Figure 
2 provides a hierarchical model of the suggested strength of the evidence provided and 
modified by Burke et al. [71]. 
Figure 2 Different types of evidence that might be applied to decisions made about the efficacy of 
use of performance supplements modified from [71]. 
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2.2.3 Risks related to the use of dietary supplements in sport 
The online expansion of the advertising and marketing of dietary supplements, due to the 
free sale of products, the lack of a uniform and adequate regulation and the manufacturer 
reluctance to adopt the FDA cGMP guidelines, are the causes of several risks for 
consumers and start to be the reason of a public health problem [53, 54]. Indeed, the 
exposition to those risks can cause toxicity and side effects, including allergic reactions, 
overexposure and poisoning due to contaminants [50]. Cases of supplements containing 
herbal extracts that caused liver, kidney and heart toxicity, have been reported [72, 73]. 
During an inspection, the presence of one or more contaminants such as lead, arsenic, 
mercury, cadmium, or pesticide trace amounts in 93% of the supplements analyzed, has 
been reported [53, 74]. “In Fiscal Year 2017, it was reported that approximately 23.48% of 
the FDA’s 656 total cGMP inspections resulted in citations for failing to establish 
specifications for the identity, purity, strength, and composition of dietary supplements. 
Further, 18.47% were cited for failing to establish and/or follow written procedures for quality 
control operations” [60]. 
The consumption of contaminated supplements can affect not only health, but can be also 
the cause of social-moral damages and penalties. This may occur when supplements are 
contaminated with substances prohibited in sport [54].  
In this regard, presence of several cases of substances not listed on label and banned by 
the (WADA) were reported either due to cross contamination or intentional contamination 
and the most frequently reported components in these supplements were anabolic steroids 
or stimulants [1-7, 10, 13-17]. It is not possible to guarantee complete safety of the products, 
this is why athletes are guided to make systematic and informed decision about the 
supplements they want to use and be able to assess the pros (benefits) and cons (harm) 
[75] (in Figure 3 is reported a guide to make an informed decision modified from [59]).
However, this is not the only problem derived from the consumption of supplements.
Another issue is the lack of precision, in terms of quantity, in the labeling of the products.
Indeed, cases of substances added in smaller or even larger amounts than the one declared
or moreover, cases in which the active ingredients of dietary supplements may be omitted
or in which the indication on the label is very generic (preventing a correct qualitative
interpretation of the composition of a product), are reported [4, 6-9, 11, 12, 15, 16]. Other
studies reported that contamination levels are observed within a single production batch
and even within a single packaging and additional active compounds possibly present in
the product, are often unknown [76].
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Figure 3 Guide informed decision making and reducing risk of Anti-Doping Rules Violations (ADRV) 
during ergogenic supplement use modified from flow chart [59]. 
Level of evidence:  
Anecdotal or ’conventional wisdom’ from 
single or a few isolated sources or available 
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Adverse reaction known? 
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Known manufacturer with good history and 
practice? 
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2.3 Doping in Sport 
The term “doping” is used to describe the administration or use of a substance foreign to 
the body or any physiological substance taken in an abnormal quantity by a competing 
athlete with the intention of increasing in an artificial and unfair manner his or her 
performance in competition [77, 78]. Doping is used to illicitly increase short-term acute 
responses and long-term adaptation, in order to raise the level that athletes could reach by 
training alone [79, 80]. The prevalence of different drugs and doping procedures will differ 
accordingly to the specific demands of each sport [79]. Historically, the control of doping in 
sport dates back to the early 1960s, when the International Olympic Committee (IOC) 
constituted its Medical Commission, and, later on the Subcommission “Doping and 
Biochemistry in sport” (reviewed in [81, 82]). The Subcommission ruled all anti-doping 
activities worldwide until the constitution of the WADA. 
2.3.1 World Anti-Doping Agency 
The WADA was established in 1999 as an independent, international agency aiming to 
create an environment in competitive sports that is doping-free and to support high-quality 
research in order to stay update and one step ahead of athletes and organizations who 
attempt to illegally enhance performances [83]. Sports are guided by rules and codes and 
the most well-known of these is the “World Anti-Doping Code” (WADC) [84]. The document 
is based on five international standards and provides consistency of anti-doping programs 
across sports and across international borders with the aim to bring consistency among 
anti-doping organizations [83]. It covers testing and investigations, laboratories, therapeutic 
use exemptions, the list of prohibited substances and methods, and protection of privacy 
and personal information. The Code requires frequent updating to adapt to changing 
knowledge [83]. 
The Prohibited List 
Prohibited substances and methods may be included in the WADA prohibited list of 
substances and methods [85] if they meet two of the following criteria:  
• The substance or method has the potential to enhance, or does enhance,
performance in sport.
• The substance or methods have the potential to risk the athlete’s health.
• WADA has determined that the substance or methods violates the spirit of sport.
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The WADA list clusters its doping categories into: ‘Substances and Methods Prohibited at 
All Times (in- and out of competition)’, ‘Substances and Methods Prohibited In-Competition’, 
and ‘Substances Prohibited in Particular Sports’ [83].  
The Monitoring Program and other substances 
Not all ergogenics are banned from sport. Some substances in fact, while not prohibited, 
are monitored to assess their use and to guide future changes to the list. An example is 
caffeine, which has strong research evidence for its efficacy [86-88]. 
For this reason, in addition to the list of prohibited substances, there is also a list of 
monitored substances. WADA, after consultation with signatories and governments, 
monitors those substances in order to detect patterns of misuse in sport. WADA publishes, 
before any testing, the substances that will be monitored [89]. After that, WADA accredited 
Doping Control Laboratory will report to WADA possible cases in which some of the 
monitored substances are detected in-competition or out-competition periodically, on an 
aggregate basis, by sport [89]. The reported use or detected presence of a monitored 
substance does not constitute an anti-doping rule violation [89]. 
Furthermore, some substances which demonstrated to have enhancing promoting effects 
are currently neither  included on the prohibited list nor on the monitoring list [90]. 
2.4 Doping Control Analysis 
Anti-doping analysis exists to detect the use of prohibited substances with established and 
validated screening and confirmation methods. Even if anti-doping analysis may be 
considered as an area of forensic toxicology, it constitutes a specific field, thus, exclusive 
application and requirements are needed. In order to have uniform, harmonized results 
reported by all laboratories and to ensure the validity of tests results and evidentiary data, 
the International Standard for Laboratories (ISL) was established [91]. The ISL includes 
several Technical Documents (TD) and it consists in a set of specific rules applicable to 
anti-doping analysis combining the knowledge of international experts in different analytical 
fields and it is regularly updated [92]. 
The analyses are performed at an International level by the anti-doping laboratories 
accredited by WADA, which as of December 1st 2019 are a total of 26, distributed worldwide 
[93]. The majority of these analyses are performed using urine specimens as the matrix 
rather than blood. Urine, indeed, allows for non-invasive collection of even relatively large 
volumes. Nevertheless, blood testing is recently increasing [94, 95]. Blood is more suitable 
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than urine to establish dose/effect response of a substance [95, 96]. Furthermore, when 
evaluating specific markers of an athlete’s steroidal profile in urine, different factors can 
negatively influence the analysis (resulting in a high rates of false negatives), which could 
be avoided using blood as matrix [95, 97-105]. For doping control purpose, samples are 
collected in two separated aliquots (A-and B-sample) of the same sample and are labelled 
with a code number to preserve the anonymity of the athlete. Analyses include a first 
screening applied to all samples, which should be fast, selective and sensitive to avoid 
false-negative results. This is followed by confirmatory analysis in case of suspicious 
screening test samples results in order to avoid false positives. These analyses are 
performed during training and competition periods, by targeting the identified compound 
or/and its metabolites. In case of an adverse analytical finding (AAF), before sanctioning, 
the supervised analysis of the B-sample can be requested [94, 106, 107].  
2.4.1 Historical development of doping control analysis and 
analytical challenges 
The evolution of pharmacology in recent years has opened the access to athletes of a large 
number of drugs more difficult to detect [92]. 
In order to understand the analytical challenges that have occurred over the last 40 years, 
it is necessary to pay attention to different aspects that influence the practices used today.  
The first official anti-doping testing at Olympic Games was in 1972 at the Summer Olympic 
Games in Munich. On this occasion, only stimulants, narcotics and drugs of abuse were 
included in the list of prohibited substances and gas chromatography utilizing flame 
ionization detection (FID) and mass spectrometry (MS) was the only reliable method [108-
110] .
At that time all the abused substances were xenobiotics (from the Greek words
ξένος (xenos) = foreigner, stranger and βίος (bios) = life), meaning not naturally present in
the body, and their pharmacokinetic profile was satisfactorily known. In addition to that, to
obtain an enhancing effect in competition, the administered doses of those substances were
high enough to result in high concentrations of drug and metabolites in urines. Furthermore,
their intake was followed only for several hours [111].
In 1976, when AAS have been included in the list of prohibited substances of the IOC, the
traditional methods used for the other doping agents and straightforward sample
pretreatment were ineffective if applied to steroids [110, 111].
Indeed, in contrast to stimulants and narcotics, the efficacy of steroids is maximum if their
intake takes place during training (starting months before), stimulating muscle growth,
Background 13 
strength and power. As consequence, if the collection of urines for the anti-doping analysis 
is performed at the competition, the concentration of steroids can be really low, resulting in 
a (false) negative response [111]. Additionally, steroids are extensively metabolized and 
excreted in the urine as glucuronides or sulfates. Therefore they need a sample preparation 
involving hydrolysis or direct targeting of the conjugates. An extraction of the deconjugated 
steroid using liquid-liquid extraction (LLE) or in some cases, solid phase extraction (SPE), 
for the concentration of the analytes is requested before analysis [106, 107, 111, 112]. 
With the introduction of MS coupled with gas chromatography (GC-MS) into routine 
screening, further followed by GC-high resolution mass spectrometry (HRMS), among the 
anti-doping analysis, the detection of AAS in urine became not only possible but even more, 
their detection window was up to several weeks from the time of the last administration 
[111]. 
GC-MS based techniques, which involve derivatization for sample preparation, became the 
primary analytical method used in laboratories for the detection and quantitation of most of 
the steroids and other doping substances.  
With the inclusion of new classes of low molecular weight, hydrophilic, thermolabile, 
nonvolatile substances in the Prohibited List, the use of MS coupled with liquid 
chromatography (LC-MS) took hold and new methods were designed, developed and 
validated. Those techniques have made possible the detection of those new prohibited 
drugs, that were partly or completely undetectable with GC-MS, reducing the extensive and 
time-consuming sample preparation procedures, the derivatization steps, improving the 
detection limits and allowing direct analysis of conjugated metabolites [113, 114]. 
2.4.2 Analytical methodologies currently used in anti-doping 
analysis 
Even though the continuing advance of LC coupled with MS or (tandem) MS (MS/MS) in 
anti-doping analysis, GC-MS(/MS) with electron ionization (EI) is still undeniable. 
Particularly concerning anabolic agents, it is still an analytical technique used in sport drug 
testing to monitor prohibited substances based on targeted approaches [114, 115]. 
LC-MS(/MS) with electrospray ionization (ESI) and more recently ultra-high performance 
liquid chromatography (UHPLC)-ESI-MS(/MS) based procedures, are able to screen for a 
considerable number of different analytes or classes of analytes in a single chromatographic 
run and to characterize phase I and phase II metabolites. 
LC-MS/MS systems equipped with new generations of mass spectrometers are used for 
the detection of a wide range of known or unknown substances. Indeed, relying on targeted 
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approaches, it is possible to identify compounds already characterized, whether operating 
in full scan mode allows to detect unknown targets [113].  
Currently, Quadrupole-Time-of-Flight (QTOF) mass analyzers are the commonly used for 
high-resolution MS in doping control analysis (LC-HRMS or GC-HRMS).  
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3 Steps on the Investigation of Ecdysterone 
3.1 Analytical Profiling of Supplements Labelled to contain 
Ecdysterone 
Twelve commercial dietary supplements (all in the dosage form of capsules) available on 
internet and labelled to contain ecdysterone have been purchased, with the aim to 
determine their actual ecdysterone content. For this purpose, different extraction 
procedures have been evaluated, using one of the products as model supplement (Peak 
Ecdysone). An analytical method, which allowed the quantitative determination of 
ecdysterone in the supplements with reasonable accuracy and precision and not time 
consuming, had to be developed and fully validated according to the guidelines of the 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH), USP 42/41 and AOAC guidelines. For the 
determination of ecdysterone content in the supplements, two different quantitative analysis 
approaches have been considered and compared: standard addition method and external 
calibration. A study to evaluate the influence of the matrix effect has been performed. 
Analyses were carried out by UHPLC-MS/MS and the mass spectrometer was operated in 
dynamic multiple reaction monitoring (dMRM) acquisition mode (manuscript 1). 
3.2 Effects on Sports Performance and Diagnostic Markers 
In order to investigate the effects of a long-term administration of an ecdysterone containing 
product on human sport exercise, a ten-week intervention study of strength training of 46 
healthy male subjects has been carried out. With this purpose, different doses of the dietary 
supplement “Peak Ecdysone”, labelled to contain 100 mg of ecdysterone per capsule from 
spinach extract, have been administered to the subjects. The study was conducted in a 
double blind, placebo controlled design. 
Volunteers were divided as followed: two training groups, ecdysterone1 group (Ec1) and 
ecdysterone2 group (Ec2), which took two or eight capsules per day respectively; one non-
training control group (COG), which took two capsules per day as Ec1, and one placebo 
group (PLG), which was training without taking any ecdysterone containing supplement. 
After ten weeks of treatment, anthropometrical (body weight, muscle mass, fat mass and 
totally body water) and performance parameters (power and strength performance) have 
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been evaluated. C2C12 cells, a myoblast cell line derived from murine satellite cells, have 
been used as in vitro model, to study muscle hypertrophy through ecdysterone. 
The supplement administered has been analyzed to determine its amount of ecdysterone 
by standard addition method, using UHPLC-MS/MS (manuscript 1). The analysis of the 
supplement for confirmation of the absence of anabolic steroid cross-contamination in the 
product was adapted from already reported methods for steroids and was carried out using 
GC-QTOF-MS and LC-QTOF-MS.  
Serum and urine specimen have been collected at different times of the study: pre-test (t1), 
after five weeks of training period (thalf) and after ten weeks of training and supplement 
administration period (t2). 
Blood serum samples have been analyzed to investigate potential effects of ecdysterone, 
training and combinations thereof on the endocrine system using specific enzyme-linked 
immunosorbent assay (ELISAs). Therefore, analyses of serum concentrations of the 
biomarkers of liver and kidney toxicity were performed by the accredited medical analytics 
laboratory Dr. Wisplinghoff of Cologne, Germany. Finally, all the serum samples were 
analyzed by LC-MS/MS to establish their concentration of ecdysterone. Two different 
sample preparation procedures, namely protein precipitation (PPT) and SPE, have been 
evaluated and optimized. The validation of the method has been carried out according to 
the guidelines “Bioanalytical Method Validation” published by the US-FDA and to the 
“Gesellschaft für Toxikologische und Forensische Chemie” (GTFCh).  
Additionally, urine samples have been analyzed with LC-MS/MS according to anti-doping 
screening routine analysis, in order to exclude intentional or unintentional co-administration 
of substances prohibited in sports. Furthermore, the study of the urinary profile of 
endogenous anabolic androgenic steroids (EAAS), in agreement with the WADA TD 2016 
EAAS “Markers of urinary steroid profile” [116], has been carried out to provide evidence 
on any biological influences induced by the administration of ecdysterone, using GC-
MS/MS. All the analyses on urine samples were performed in accordance with the 
procedures used in the WADA accredited Anti-Doping Laboratory of Rome, Italy 
(Laboratorio Antidoping Federazione Medico Sportiva Italiana, (FMSI)) (manuscript 2-3).  
3.3 Investigation of the Urinary Metabolic Profile of Ecdysterone 
Analytical properties of ecdysterone have been investigated after administration of a single 
dose (51.5 mg) of pure ecdysterone to one healthy volunteer. Post-administration urine 
samples have been collected for 33 hours, and spot urines in the following 3 days.  
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Extraction procedures have been evaluated using ecdysterone reference as model 
compound. They included LLE, at different pH values and with different solvents, or SPE, 
with different cartridges. The recovery of ecdysterone has been evaluated performing 
analysis with LC-MS/MS.  
The sample preparation of post-administration urines have included enzymatic hydrolysis 
with β-glucuronidase or a mixture of β-glucuronidase and arylsulfatase for the evaluation of 
a potential phase II-metabolism or simply dilution of urines with water (1:4) before injection. 
The presence of ecdysterone in post- administration urines has been confirmed by 
comparison with reference material. The evaluation of the presence of a desoxy metabolite 
in post-administration urines has been carried out through the comparison with reference 
standard material of 20-desoxy-ecdysterone (ecdysone or α-ecdysone) and 25-desoxy-
ecdysterone (ponasterone), and with in-house synthetized 14-desoxy-ecdysterone 
(synthesis according to Kumpun et al. [31]). Analyses of the mass spectrometric properties 
of the reference materials have been performed with LC-ESI-QTOF-MS and GC-EI-QTOF-
MS. The investigation of ecdysterone metabolites in post-administration urine samples was 
performed using LC-QTOF-MS in MS1 mode, with LC-QTOF-MS/MS experiments for 
confirmation. The resulting excretion profiles of ecdysterone and possible metabolites have 
been evaluated (manuscript 4). Figure 4 graphically summarizes the different steps of the 
investigation on ecdysterone.   
Figure 4 Different steps of the investigation on ecdysterone. 
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4 Publications 
4.1 Manuscript No. 1 
“How reliable is dietary supplement labelling? - Experiences from the analysis of 
ecdysterone supplements” 
Gabriella Ambrosio, Dave Wirth, Jan Felix Joseph, Monica Mazzarino, Xavier de la Torre, 
Francesco Botrè, Maria Kristina Parr 
Journal of Pharmaceutical and Biomedical Analysis 177 (2019) in press 
https://doi.org/10.1016/j.jpba.2019.112877 
The present study aimed to design, develop, and optimize an analytical procedure to 
perform the quantitative determination of ecdysterone in commercially available dietary 
supplements. The newly developed procedure is based on the extraction of ecdysterone 
from the supplements and the subsequent analysis by an optimized UHPLC-MS/MS 
method. Chromatographic separation was performed on an Agilent Eclipse Plus C18 
column (2.1 mm x 100 mm, particle size 1.8 μm). The mass spectrometer was operated in 
positive ionization mode (ESI+) with acquisition in dynamic multiple reaction monitoring 
(dMRM) mode. Using the protonated molecular ion [M+H]+ ecdysterone (target) and cortisol 
(internal reference) were detected at m/z 481 and 363, respectively. The assay was 
fully validated according to ICH guidelines and the method resulted to be fit for purpose in 
terms of accuracy and precision (CV% and RE% <15). Time-different intermediate 
precision was found within the reported range according to AOAC guideline for dietary 
supplements and botanicals. Quantitation has been performed using an external 
calibration considering the minimal matrix influences, preliminarily assessed following a 
cross comparison with an elaborate and time consuming standard addition method. 
The method was successfully applied to12 different dietary supplements labelled to 





4.2 Manuscript No. 2  
 
“Ecdysteroids as non-conventional anabolic agent: performance enhancement by 
ecdysterone supplementation in humans” 
 
Eduard Isenmann, Gabriella Ambrosio, Jan Felix Joseph, Monica Mazzarino, Xavier de la 
Torre, Philipp Zimmer, Rymantas Kazlauskas, Catricn Goebel, Francesco Botrè, Patrick 
Diel, Maria Kristina Parr 
 
Archives of Toxicology 93 (2019) 1807-1816 
https://doi.org/10.1007/s00204-019-02490-x 
 
Recent studies suggest that the anabolic effect of ecdysterone, a naturally occurring steroid 
hormone claimed to enhance physical performance, is mediated by estrogen receptor (ER) 
binding. In comparison to the prohibited anabolic agents (e.g. metandienone and others) 
ecdysterone revealed to be even more effective in a recent study performed in rats. 
However, scientific studies in humans are very rarely accessible. Thus, our project aimed 
at investigating the effects of ecdysterone containing products on human sport exercise. A 
ten-week intervention study of strength training of young men (n=46) was carried out. 
Different doses of ecdysterone containing supplements have been administered during the 
study to evaluate the performance enhancing effect. Analysis of blood and urine samples 
for ecdysterone and potential biomarkers of performance enhancement have been 
conducted. In order to ensure the specificity of the effects measured, a comprehensive 
screening for prohibited performance enhancing substances was also carried out. 
Furthermore, the administered supplement has been tested for the absence of anabolic 
steroid contaminations prior to administration. Significantly higher increases in muscle mass 
were observed in those participants that were dosed with ecdysterone. The same 
hypertrophic effects were also detected in vitro in C2C12 myotubes. Even more relevant 
with respect to sports performance, significantly more pronounced increases in one-
repetition bench press performance were observed. No increase in biomarkers for liver or 
kidney toxicity were noticed. These data underline the effectivity of an ecdysterone 
supplementation with respect to sports performance. Our results strongly suggest the 
inclusion of ecdysterone in the list of prohibited substances and methods in sports in class 






4.3 Manuscript No. 3  
“Detection and quantitation of ecdysterone in human serum by liquid 
chromatography coupled to tandem mass spectrometry” 
Gabriella Ambrosio, Jan Felix Joseph, Bernhard Wüst, Monica Mazzarino, Xavier de la 





The polyhydroxylated phytosteroid ecdysterone is present in various plants (e.g. spinach). 
It is widely marketed as the active component of dietary supplements, due to its reported 
health and performance promoting effects. For evaluation of its actual bioavailability, a fast 
and sensitive method was developed, optimized and validated for human serum. 
Instrumental analysis was performed utilizing liquid chromatography-tandem mass 
spectrometry with positive electrospray ionization and acquisition in multiple reaction mode. 
Solid phase extraction and dilute-and-inject (following protein precipitation) were tested to 
isolate ecdysterone from human serum. Both methods were compared in the light of the 
preset analytical target profile. The limit of detection (LOD) and quantification (LOQ) for 
ecdysterone in human serum after SPE extraction corresponded to 0.06 ng/mL and 0.14 
ng/mL, respectively, meeting the requested sensitivity of the method. The assay was linear 
over the range from 0.10 ng/mL to 20.83 ng/mL. As expected, the sensitivity of the SPE 
method was better than that of the dilute-and-inject procedure, which did not allow for 
quantification of all post administration serum samples. 
Accuracy (relative error; %) and precision (coefficient of variation; %), were both within 
acceptance criteria (<15%).  
The developed method was successfully applied to a ten week intervention study conducted 
in young men performing regular resistance training. Different doses of supplements 
containing ecdysterone from spinach extract have been administered during the study and 
the quantitation of ecdysterone in serum samples has been successfully conducted. 
Ecdysterone could be quantified in all post-administration samples using solid phase 
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• An UHPLC/MS/MS assay to quantify ecdysterone in human serum has been developed.
• The method was applied to a ten week intervention study conducted in young men.
• For sample pretreatment solid phase extraction (SPE) has been used.




The polyhydroxylated phytosteroid ecdysterone is present in various plants (e.g. spinach). It is widely marketed as the 
active component of dietary supplements, due to its reported health and performance promoting effects. For evaluation 
of its actual bioavailability, a fast and sensitive method was developed, optimized and validated for human serum. 
Instrumental analysis was performed utilizing liquid chromatography-tandem mass spectrometry with positive 
electrospray ionization and acquisition in multiple reaction mode. Solid phase extraction and dilute-and-inject 
(following protein precipitation) were tested to isolate ecdysterone from human serum. Both methods were compared in 
the light of the preset analytical target profile. The limit of detection (LOD) and quantification (LOQ) for ecdysterone in 
human serum after SPE extraction corresponded to 0.06 ng/mL and 0.14 ng/mL, respectively, meeting the requested 
sensitivity of the method. The assay was linear over the range from 0.10 ng/mL to 20.83 ng/mL. As expected, the 
sensitivity of the SPE method was better than that of the dilute-and-inject procedure, which did not allow for 
quantification of all post administration serum samples. 
Accuracy (relative error; %) and precision (coefficient of variation; %), were both within acceptance criteria (<15%).  
The developed method was successfully applied to a ten week intervention study conducted in young men performing 
regular resistance training. Different doses of supplements containing ecdysterone from spinach extract have been 
administered during the study and the quantitation of ecdysterone in serum samples has been successfully conducted. 
Ecdysterone could be quantified in all post-administration samples using solid phase extraction (SPE) for sample 
















Ecdysteroids are polar, polyhydroxylated steroids involved in the molting of insects and crustaceans. They are also 
present in a variety of plants such as spinach (Spinacia oleracea L.) and are among the main bioactive components of 
herbs. In spinach, the most abundant ecdysteroid is ecdysterone (chemical structure Fig.1a) which, depending on the 
growth rate of the plant, is present in a concentration range between 50 and 800 µg/g [1, 2]. 
Several studies conducted in-vitro and in animals have reported a variety of pharmacological effects of ecdysterone: an 
increase in carbohydrate and fatty acid metabolism, the stimulation of immune response, and an enhancement in protein 
synthesis, and physical power [3, 4]. Ecdysterone is advertised to increase strength and muscle mass during resistance 
training, to reduce fatigue, to ease recovery, and to induce anabolic effects, without any of the classical side effects of 
anabolic androgenic steroids, such as virilization [2, 5, 6]. Also for these reasons, ecdysterone has been marketed as 
dietary supplement for athletes.  
Extensive investigations on the possible growth-promoting effects of ecdysterone in various animal species (rats, mice, 
Japanese quail and cattle) with a few studies recently performed also in humans, have been reported [2, 6-20]. There are 
several anecdotal reports on ecdysterone misuse by athletes, but only few scientific studies are available to demonstrate 
its potential performance enhancing effects.  
Mechanistically, ecdysterone has been characterized as devoid of binding ability to either androgen receptor (AR), 
estrogen receptor (ER, where ERalpha was targeted), or glucocorticoid receptor [17, 21]. Only recently, binding of 
ecdysterone to the ERbeta could be shown in-vitro and in-silico [2, 22, 23].  
In this study, we report the development and validation of a method based on liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) for the identification and quantitation of ecdysterone in human serum. As proof of concept 
this method was applied to serum samples obtained from a ten week intervention study conducted in young men after 











Fig. 1. Chemical structure of (a) ecdysterone and (b) ponasterone (used as internal standard). 
 









2.1. Chemicals and materials 
Ecdysterone (2β,3β,14α,20β,22R,25-hexahydroxy-5β-cholest-7-en-6-one, purity>95%) and ecdysone 
(2β,3β,14α,22R,25-pentahydroxy-5β-cholest-7-en-6-one, used for selectivity testing of the method) were purchased from 
Steraloids (Newport, USA). Ponasterone (2β,3β,14α,20β,22R-pentahydroxy-5β-cholest-7-en-6-one), used as internal 
standard (ISTD), was obtained from Cayman Chemical Company (Ann Arbor, Michigan USA). Methanol, LC-MS grade, 
was purchased from J.T. Baker, acetonitrile, LC-MS grade, from Fisher Scientific GmbH (Schwerte, Germany), and 
formic acid, LC-MS grade, from Honeywell International Inc. (Bucharest, Romania). A Milli-Q water purification system 
LaboStar 2-DI/UV to obtain purified water for the analysis was obtained from SG Wasseraufbereitung und 
Regenerierstation GmbH (Barsbüttel, Germany). Blank human serum (male, USA) was obtained from Sigma Aldrich 
(Taufkirchen, Germany) and stored at -18 °C until use.  
Oasis HLB 3cc Vac cartridges (60 mg sorbent per cartridge, 30 µm particle size) were purchased from Waters GmbH 
(Eschborn, Germany) and were used for the extraction of the target ecdysterone from the serum.  
2.2. Instrumentation 
The instrumental analyses were carried out using an ultrahigh performance liquid chromatography tandem mass 
spectrometry (UHPLC-MS/MS) system (Agilent 1290 Infinity II UHPLC coupled to an Agilent 6495 triple quadrupole 
tandem MS system, Agilent Technologies GmbH, Waldbronn, Germany) utilizing an Agilent Jet Stream ESI source and 
Ion Funnel. 
Chromatographic separation was achieved on an Agilent Eclipse C18 column (2.1 mm x 100 mm, particle size 1.8 μm). 
A linear gradient (10% B for 2 min, linear increase to 90% in 4 min, 1 min hold, in 0.5 min back to 10% B for 
reequilibation) was used with aqueous formic acid (H2O:formic acid, 99.9:0.1, v:v, eluent A) and acetonitrile:formic acid 
(99.9:0.1, v:v, eluent B) as mobile phase constituents at a flow rate of 0.5 mL/min. The total run time was 7.5 min and 
the column equilibration time after each run was 2.5 minutes. The sample injection volume was 5 µL. The temperature 
of the autosampler was maintained at 5°C.  
Table 1  













ecdysterone       
quantifier 3.78 481 371 12 4 positive 
qualifier 3.78 481 445 12 5 positive 
qualifier 3.78 481 165 28 5 positive 
ponasterone
quantifier 4.5 465 109 32 6 positive 
qualifier 4.5 465 173 24 6 positive 
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The mass spectrometer was operated in positive electrospray ionization (ESI+). A capillary voltage of 3.500 V, a nozzle 
voltage of 300 V, a drying gas flow of 15 L/min (nitrogen) at 150°C, sheath gas flow of 12 L/min (nitrogen) at 375°C 
and a nebulizer pressure of 25 psi (nitrogen) were used. The protonated molecular ion [M+H]+ for ecdysterone and 
ponasterone (ISTD) were detected at m/z 481 or 465, respectively. Ecdysterone was detected by the ion transition 
481→371 (quantifier), 481→445 (qualifier 1) and 481→165 (qualifier 2). For the detection of the internal standard the 
ion transition 465→109 (quantifier) and 465→173 (qualifier), were used. Fig. 2 shows the corresponding 
chromatograms. The MS parameters were fine-tuned for maximum sensitivity, and ion transitions were selected to 
obtain the best response (for the spectrum analysis). Details of MRM transitions, retention time, collision energy, cell 
accelerator voltage and polarity applied for ecdysterone and ISTD are shown in Table 1. A diverter valve of the LC 
system was used to minimize the influence of the matrix interfering substances on MS analysis (though source 
contamination) [24]. This valve was open during the first 3.5 minutes of the chromatographic run and after 5 minutes, 
avoiding contamination of the ESI source considering that the elution time of ecdysterone and its internal standard was 
between 3.5 and 5 minutes. Mass Hunter software from Agilent was used for data acquisition and processing. 
Fig. 2. MRM chromatograms and product ions of ecdysterone (a) and ponasterone (b) (ISTD). Chromatograms 








2.3. Preparation of standard solutions and quality control samples 
Stock solutions of ecdysterone and ponasterone (ISTD) were prepared in methanol at a concentration of 1 mg/mL and 
stored at -18°C. Working standard solutions of ecdysterone and ISTD were prepared by dilution of stock solutions in 
methanol. The working solutions of ecdysterone were diluted by methanol before preparation to obtain 0.5, 2.5, 5, 25, 
50, 100, 200, 300, 400 and 500 ng/mL reference solutions, that were used for spiking and for preparation of the 
calibrants. The final concentrations of ecdysterone in the standard calibration plasma samples were 0.02, 0.10, 0.21, 
1.04, 2.08, 4.16, 8.33, 12.5, 16.66 and 20.83 ng/mL (matrix matched standards).  
The quality control samples (QC) were independently prepared at three levels of concentration for ecdysterone: 
0.21 ng/mL (low concentration QC, LQC), 8.33 ng/mL (medium concentration QC, MQC), and 16.66 ng/mL (high 
concentration QC, HQC) spiked in blank plasma.  
 
2.4. Evaluation of pre-analytical sample processing 
2.4.1. Protein precipitation (PPT) 
The efficiency of the protein precipitation step was optimized by evaluating different solvents, i.e. acetonitrile and 
methanol, in different proportions with the serum. The most suitable solvent for the PPT was cold methanol. Therefore 
the final preparation was performed adding to 50 µL of human serum, 40 µL of ice cold HPLC-MS grade methanol and 
5 µL of diluted standard methanolic solutions of both ecdysterone and ISTD. A subsequent centrifugation for 15 
minutes, at a relative centrifugal force (RCF) =2490*g and 20°C to separate the precipitated proteins followed. Aliquots 
of 5 µL of the supernatants were injected in the UHPLC-MS/MS system. 
 
2.4.2. Solid phase extraction (SPE) 
Due to the unsuitability of a liquid-liquid extraction (LLE) which was carried out using t-butyl methyl ether and ethyl 
acetate, resulting in recoveries of ecdysterone lower than 5 and 10%, respectively, a solid phase extraction (SPE) has 
been performed.  
For this purpose, 480 µL of human serum were diluted with 480 µL of ultra-purified water and 20 µL of ecdysterone 
reference solution (working solutions of  0.5, 2.5, 5, 25, 50, 100, 200, 300, 400, and 500 ng/mL), and 20 µL of ISTD 
(150 ng/mL). The samples were vortexed and loaded onto HLB OASIS cartridges. Before sample application, the SPE 
column was conditioned by 1 mL of methanol and re-equilibrated using 1 mL of ultra-purified water. After a washing 
step with 1 mL of water the samples were finally eluted using 1 mL of methanol and concentrated under stream of 
nitrogen. The residue was reconstituted in 100 µL of methanol. Aliquots of 5 µL were injected into the UHPLC-MS/MS 
system for analysis.  
 
2.5. Pretreatment of study samples 
The serum samples (480 µL) were diluted with 480 µL of ultra-purified water and 40 µL of ISTD (working solution 
75 ng/mL) were added. To isolate ecdysterone and the ISTD from the human plasma, the samples were vortex mixed 
for 5 seconds and then loaded onto the HLB OASIS cartridges.  
Loading was performed after previous conditioning and re-equilibration of the cartridges with a flow of 1 mL/min to 








The analytes were eluted with 1 mL of methanol and reconstituted with 100 µL of methanol, after eluates were 
evaporated under stream of nitrogen and 5 µL of the samples were finally injected in the UHPLC-MS/MS system for 
the analysis. 
 
2.6. Validation of the final analytical procedure  
The analytical procedure was validated in terms of selectivity, limits of detection (LOD) and quantification (LOQ), 
linearity, accuracy, recovery, ion suppression/enhancement, intra-day and inter-day precision. Validation was 
performed in accordance to the guidelines “Bioanalytical Method Validation” published by the US-Food and Drug 
Administration (FDA, [25]) and to the “Guidelines for quality assurance in forensic-toxicological analyses requirements 
for the validation of analytical methods” [26].  
 
2.6.1. Selectivity  
The selectivity was studied by comparing the LC-MS/MS signals, acquired in MRM mode, of blank serum with those 
of serum samples spiked with ecdysterone (C27H44O7), ponasterone and ecdysone (both C27H44O6) at LQC 
(c=0.21 ng/mL, MQC (c=8.33 ng/mL) and HQC (c=16.66 ng/mL) levels. 
 
2.6.2. Response function, LOD and LOQ 
For the response function different aliquots of blank serum spiked with ecdysterone at ten concentration levels from 
0.02 ng/mL to 20.83 ng/mL were prepared in duplicate. Calibration curves were constructed by least-squares linear 
regression of the peak area ratio of ecdysterone to ISTD (y-axis) and the nominal standard concentration (x-axis), 
described as  =  + . Testing the homogeneity of variance was performed according to DIN 38402 T51 including 
the test for outliers by using the Grubbs test. In order to verify the homogeneity of variances (n=10) standard samples of 
each of the lowest and highest concentration of the preliminary range have been analyzed. The variances of both series 
of measurements have been checked for homogeneity using the F-test.  
Back calculations were performed to determine the concentration of ecdysterone in each calibration standard and the 
resulted calculated parameters were used to quantify the concentration of analytes in QCs or unknown samples using 
Mass Hunter Quant Software from Agilent. The Grubbs test for outliers was performed according to the GTFCh 
“Guidelines for quality assurance in forensic-toxicological analyses requirements for the validation of analytical 
methods”. A correlation coefficient (R2)>0.990 was considered satisfactory. The linearity test according to Mandel was 
assessed by a linear regression using appropriate weighting. The LOD and the LOQ were determined based on the 
uncertainty of the calibration according to DIN 32645. Representative chromatograms of authentic study samples with 
concentrations close to the calculated LOQ are available as supplemental material. 
 
2.6.3. Accuracy and precision 
The intra-day accuracy and precision were evaluated with 10 replicates of QC samples at three different concentrations 
(low, medium, high). Calculation of the concentration was performed from the ratios of the areas of ecdysterone and its 
ISTD using Mass Hunter Quant software and matrix matched calibrants. Accuracy was expressed as the percent relative 
error (RE%) and the assay precision was calculated by the percent coefficient of variation (CV%conc). The acceptance 
values used for validation of RE% and CV%








precision was evaluated running analysis of variance (ANOVA), by injecting 5 individually prepared replicates on 3 
different days of the serum spiked with ecdysterone and its ISTD at concentration of 8.33 ng/mL (MQC).  
 
2.6.4. Recovery and matrix effect 
The recovery percent of ecdysterone was determined by comparing the ratios of the areas of ecdysterone and the ISTD 
of extracted LQC, and HQC (0.21 and 16.66 ng/mL) with post-extraction spiked samples. The matrix effect of 
ecdysterone was determined by comparing the ratios of the areas of ecdysterone and its ISTD in post-extraction spiked 
sample in blank human serum to those obtained from the standard solutions in methanol at the HQC. Analyses were 
performed in six replicates.  
 
2.6.5. Retention time repeatability, carry over, auto sampler stability 
The retention time of characteristic ion transition repeatability was evaluated by injecting 5 times on 3 different days the 
serum samples spiked with ecdysterone and its ISTD at a concentration of 8.33 ng/mL (MQC). Carry over was tested by 
running pure methanol injections after each series of calibrators. The injection was carried out twice or three times after 
the highest calibrant (c=20.83 ng/mL), to ensure no ecdysterone nor ISTD was detected in the blank samples. All the 
samples were freshly prepared before analysis. After injection of the freshly prepared samples, the stability was 
evaluated by leaving the treated samples in the auto sampler for 72 h at 5°C and reinjecting them again. 
 
 
2.7. Controlled administration study  
The performance of the validated method has been assessed to quantify ecdysterone concentrations in serum of human 
male subjects.  
The human intervention trial [20] was approved by the local ethical committee of German Sport University Cologne, 
Germany (No. 067/2016). Forty-six healthy male subjects successfully completed the study that was carried out in 
double blind design. The participants were assigned to four different groups: Placebo-group (PLG, n=12), Spinach1-
group (SP1G, n=12), Spinach2-group (SP2G, n=10) and Control-group (COG, n=12). The PLG took two placebo 
capsules each day over a period of 10 weeks, the SP1G and COG took two capsules of “Peak Ecdysone” a day. The 
SP2G took a high dosage of ecdysterone, eight capsules of “Peak Ecdysone” each day. All participants were informed 
regarding potential risks related to the study and signed a declaration of no objection. Serum samples were collected 
from all participants prior to first administration (T1), after 5 weeks of intervention (T2) and after 10 weeks of 












3. Results  
Analytical target profile 
Prior to method development the analytical target profile was established as prerequisite for rational method 
development [27]. Criteria for the developed method are its ability to separate, detect, identify and quantify ecdysterone 
in human serum using UHPLC/MS-MS. Thus, the procedure must be able to differentiate and quantify ecdysterone and 
its ISTD in the presence of other components in the serum samples. Due to the lack of stable isotope labelled 
ecdysterone, ponasterone (25-desoxyecdysterone) was chosen as ISTD. The total run time should not exceed 10 minutes 
to allow reasonable sample throughput. Acceptance values of RE% for the accuracy and CV%conc for the precision, have 
to be within 15% (except at the LOQ where 20% are considered acceptable), indicating that ecdysterone can be 
determined in human serum samples with reasonable precision and accuracy. The calibration (standard) curve should 
cover the expected study sample concentration range. The range considered for the calibration has to follow linear 
correlation and the LOQ has to be as low as the concentration present in the post administration samples considered in 
this study as proof of concept. Recovery of the analytes should be consistent, precise, and reproducible. 
 
3.1. Comparison of extraction procedures 
The increasing interest on high throughput sample analysis has led to the common practice of preparing samples by the 
simplest and fastest possible method, which often means using PPT only. However, the specific organic solvent used in 
PPT may have dramatic effects on the overall cleanliness of the final extract [28]. 
In this study the LOQ of ecdysterone in blank serum after preprocessing using PPT and SPE were compared. Using 
PPT LOQPPT=9.92 ng/mL was found while SPE allowed for LOQSPE=0.14 ng/mL, respectively. According to 
Chemspider database, the analytes show a relatively high polarity, expressed by their reported logP values 
(logP(ecdysterone)=0.5, logP(ponasterone)=1.55, logP(ecdysone)=0.87, and for comparison logP(cortisol)=1.43, 
predicted values ACDLabs Percepta). Thus, liquid-liquid extraction was found unsuitable and recoveries of ecdysterone 
were found to be less than 5 and 10%, respectively. 
As expected, the procedure including the solid phase extraction produced better results considering the range of serum 
concentrations of ecdysterone in the controlled administration study. While analytes are diluted in protein precipitation 
(1:1.v:v), a concentration factor of 4.8 was achieved in SPE, concomitant with additional purification of the analytes. 
The Oasis HLB cartridges were selected as suitable cartridges as they contain a universal polymeric reversed-phase 
sorbent that was developed for the extraction of a wide range of acidic, basic, and neutral compounds from various 
matrices using a simple, generic protocol. Moreover, since the Oasis HLB sorbent is water wettable, it maintains its 
capability for higher retention and excellent recoveries even if the sorbent runs dry. This means there is no need to take 
extraordinary steps to keep the sorbent beds from drying out during the critical steps prior to sample loading. 
 
3.2. Selectivity 
No interfering compounds at the retention time of ecdysterone, ponasterone, or ecdysone have been detected. 











3.3. Response function, LOD and LOQ 
The linear range for the ecdysterone calibration curve was 0.10-20.83 ng/mL. The best fit was indicated by a correlation 
coefficient of ≥ 0.995. A linear regression, which did not result into significantly better description than the quadratic 
regression (p value ≤ 0.05), was determined according to DIN 38402 T51 (ISO 8466). It was used to produce the best fit 
for the analyte concentration-detector response relationship using 1/x least square weighting, after testing the 
homogeneity of variance according to DIN 38402 T51. The test of homogeneity of variance showed a significant 
difference between the variances, i.e., TV > F (f1=9, f2=9, P=99%). As consequence the weighted factor 1/x has been 
applied. LOD and LOQ were calculated according to DIN 32645 and corresponded to 0.06 ng/L and 0.14 ng/mL, 
respectively. 
 
3.4. Accuracy and precision  
The accuracy and intra-day precision were determined at the LQC (0.21 ng/mL), MQC (8.33 ng/mL) and HQC 
(16.66 ng/mL), respectively. Results are shown in (Table 2). The criteria for intra-day precision (CV < 15%) and 
accuracy (RE < 15%), indicate that ecdysterone concentrations can be determined in human serum samples with 
reasonable precision and accuracy and that the method is suitable for use in the administration study. Inter-day precision 
was performed running the analysis of variance (ANOVA) using Excel according to GTFCh “Guidelines for quality 
assurance in forensic-toxicological analyses requirements for the validation of analytical methods”, after injection of the 








± SD (ng/mL) CV (%) RE (%) 
0.21 0.24 ± 0.05 7.78 14.28 
8.33 7.75 ± 0.51 6.27 -6.96 
16.66 17.02 ± 0.59 5.36 2.16 












3.5. Recovery and matrix effect  
Respective recoveries of ecdysterone are shown in Table 3. For QC level of 0.21 (LQC) it corresponded to 100.7% 
with CV of 12.8%. At QC level of 16.66 ng/mL (HQC) the recovery was 94.4% with CV of 14.8%. The CV % at the 
LQC and HQC < 15% indicate that the method produced good and reproducible recovery for ecdysterone from human 
serum after extraction. The matrix factor was tested at the QC level of 16.66 ng/mL (HQC) and corresponding to 






 Assessment of the recovery and matrix effect of ecdysterone in human serum  
Compound Nominal concentration (ng/mL) Recovery (%, n=6) CV (%) 
Matrix effect      
(%, n=6) CV (%) 
ecdysterone 
0.21 100.7 12.8 - - 
16.66 94.4 14.8 109.9 14.5 
Each value is presented as mean. CV, coefficient of variation 
 
 
3.6. Retention time stability, carry over, and auto sampler stability 
Good repeatability of the relative retention time was tested and CV%RT < 0.05% was obtained even over several days. 
No signal different from the base line was observed injecting pure methanol after a highly concentrated sample or 
calibrant. Thus, carry-over can be considered irrelevant. No variation higher than analytical imprecision (CV < 10 %) 
were observed during this study. 
 
 
3.7. Controlled administration study 
The application of the developed and validated LC-MS/MS method utilizing SPE demonstrated that it is suitable for the 
quantification of ecdysterone in human serum. It allows for fast analysis times and sensitive quantitation of even trace 
amounts of ecdysterone. In serum samples collected before the intervention period (T1) after 5 weeks of intervention 
(T2) and after 10 weeks of intervention (T3), serum concentrations of ecdysterone were determined. Serum 
concentrations of ecdysterone are displayed as boxplots (Fig.3) grouped for 2 capsule/day, 8 capsule/day and baseline 
(no administration of supplement). All serum concentrations in the post administration samples could be quantified 









Fig. 3. Serum concentration of ecdysterone
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481.0 -> 371.0 , 481.0 -> 445.0 , 481.0 -> 165.0
Ratio = 116.0 (96.0 %)
Ratio = 59.2 (80.8 %)
Supplement 1: Chromatograms representing ion transitions of ecdysterone in authenic study samples
concentrations of ecdysterone calculated as
c(upper)=0.20 ng/mL, c(middle)=0.20 ng/mL, c(lower)=0.25 ng/mL
.   . , .   .
Ratio = 132.2 (109.4 %) 
Ratio = 60.6 (82.7 %)
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Purpose The phytosteroid ecdysterone was recently reported to enhance performance in 
sports and may thus be considered as a substance of relevance in anti-doping control. To 
trace back an administration of ecdysterone from urine samples, analytical properties have 
been investigated to assess its integration into initial testing procedures (ITP) in doping 
control laboratories.  
Methods Analytical properties of ecdysterone were evaluated using gas chromatography-
quadrupole/time-of-fight-mass spectrometry (GC–QTOF–MS) and liquid chromatography 
(LC)–QTOF–MS. Its metabolism and elimination in human were studied using urines 
collected after administration.  
Results The detectability of ecdysterone by GC–MS (after derivatization) and/or LC–
MS(/MS) has been demonstrated and sample preparation methods were evaluated. Dilute-
and-inject for LC–MS(/MS) or solid phase extraction using Oasis HLB for GC–MS or LC–
MS were found most suitable, while liquid–liquid extraction was hampered by the high 
polarity of ecdysteroids. Most abundantly, ecdysterone was detected in the post 
administration urines as parent compound besides the metabolite desoxy-ecdysterone. 
Additionally, desoxy-poststerone was tentatively assigned as minor metabolite, however, 
further investigations are needed.  
Conclusion An administration of ecdysterone can be targeted using existing procedures of 
anti-doping laboratories. Ecdysterone and desoxy-ecdysterone appeared as suitable 
candidates for integration in ITP. Using dilute-and-inject a detection of the parent compound 
was possible for more than 2 days after the administration of a single dose  
of ~ 50 mg. 
Discussion 76 
5 Discussion 
This project had to go through different stages to demonstrate the performance-enhancing 
effects deriving from a long-term administration of ecdysterone containing supplements and 
it was supported by evidences from previous studies, which reported growth promoting and 
anabolic effects of ecdysterone in various animal species and in humans [28-44], mediated 
by its binding to ERbeta receptors [29, 46, 47]. A few studies investigated on ecdysterone’s  
metabolism, most of them in mice and in rats [31, 117, 118], while those in humans differ 
for structure assignment [119, 120]. 
In this project, analytical methods were developed and validated to provide concrete and 
precise data, using different biological specimens or supplements. In parallel, an 
intervention study in humans has been carried out.  
The developed and validated UHPLC-MS/MS method allowed for determination of the 
amount of ecdysterone in dietary supplements with reasonable accuracy and precision in a 
reasonable time. All supplements have been quantified using an external calibration, 
because the matrix effect has been considered within the acceptable limits. The developed 
method allowed to evaluate the actual reliability of the information reported on the labelling 
of 12 dietary supplements. Unfortunately, the concern about consistency between their 
actual content and label is confirmed. In 67% of the supplements, the content of 
ecdysterone is much lower than indicated on the label. For some of them, the indication on 
the label is very generic, preventing a correct qualitative and quantitative interpretation of 
the composition. In addition to that, quantitative differences are identified between distinct 
batches belonging to the same dietary supplement. This shows that it is necessary to 
develop analytical methods in order to characterize the chemical composition of products 
and to avoid undesired misdosage by users, which increases the risk of side effects. Also, 
this allows to correctly correlate the effects obtained in any intervention study, with the real 
qualitative and quantitative composition of a product.  
The supplement “Peak Ecdysone” was chosen for the administration trial, due to the results 
obtained from purity control analysis and easy availability of a large number of capsules 
from the same lot. However, in the “Peak Ecdysone” supplement only 6% of the labelled 
content was found, corresponding to 6 mg/capsule. This results in an administration 
equivalent to 0.15 mg/kg and 0.6 mg/kg per day in an 80-kg volunteer if administered as 
reported in the human administration trial. Contamination of the supplements administered 
to volunteers with other performance enhancing drugs and their presence in urines, due to 
co-administration with other prohibited substances included in the anti-doping screening, 
have been excluded. Nevertheless, after ten weeks of treatment (training and/or 
supplement administration), positive time effects of ecdysterone on anthropometric (body 
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weight and muscle mass) and on strength performance (upper body strength) were 
observed. A dose-dependent effect is detected by the enhancement of the average training 
and from the fact that both ecdysterone groups (Ec1 and Ec2) increased their performance 
significantly compared to the PLG. Thus, a tendency for an enhanced performance by 
supplementation with ecdysterone was detected. These findings are corroborated by in-
vitro experiments. A hypertrophy in C2C12 myotubes after 48 hour of treatment with 
supplement extract were detected. Hypertrophy was found similar to that obtained by 
dihydrotestosterone (DHT) estradiol (E2), or pure ecdysterone reference, which were used 
as controls. On that basis, further in-vitro experiments will be performed to identify potential 
metabolites, which may be included in targeted screening methods. 
To evaluate the bioavailability of ecdysterone and to correlate serum concentrations with 
biological effects, a method for quantitation of ecdysterone in human serum has been 
successfully established and validated. As expected, the sample preparation utilizing SPE 
(Oasis HLB cartridges, 96% recovery of ecdysterone) resulted in much lower limit of 
quantification than simple PPT or LLE, considering the range of serum concentration of 
ecdysterone in the controlled administration study. Indeed, PPT was not suitable maybe 
due to non-elimination of matrix compounds, and LLE neither, due to the relative polarity of 
ecdysterone. The newly validated UHPLC-MS/MS method allowed for fast analysis and 
sensitive quantitation of even trace amounts of ecdysterone. A clear dose-dependent 
increment of ecdysterone in serum samples is detected. Variances of concentration in all 
groups most likely result from different individual pharmacokinetic parameters and slightly 
different time intervals of sample collection since the last supplements’ administration.  
No clinically relevant side effects attributable to ecdysterone supplementation were 
observed in the administration trial: serum concentration of the biomarkers of liver and 
kidney toxicity did not change significantly after 10 weeks. Between the endocrine 
hormones considered, changes can be observed for insulin like growth factor (IGF-1) and 
for thyroxin (T4). From the results obtained, training without supplementation of ecdysterone 
(PLG) resulted in a decrease of IGF-1. This can be explained with the fact that as a result 
of intensive training, cytokines, in particular tumor necrosis factor and interleukin 1, increase 
in the muscle and this effect decreases the level of IGF-1 and prevent it by acting on its 
receptors. Therefore, the intake of ecdysterone, in the case of Ec1 and Ec2, can antagonize 
this effect, resulting in an increase of IGF-1. Decreased concentrations of T4 have been 
observed in the three training groups (PLG, Ec1 and Ec2). No differences in T4 between 
the ecdysterone groups compared to the placebo have been reported. This shows that an 
intensive training, and not the administration of ecdysterone, may have an influence on T4. 
High intensive training may stimulate accelerated metabolism and stimulate changes in the 
in the body-weight regulatory hormones [121]. Variations in thyroid hormones’ 
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concentrations can be correlated to intensive training [122]. Anyway further investigations 
are necessary to assess the influence of ecdysterone or of intensive training on hormone 
expression.  
From the results obtained, no significant variation of the steroidal module parameters are 
detected in the post-administration urines, so it seems not possible to detect an ecdysterone 
intake from athletes due to an alteration of the steroidal profile. This suggests that the 
anabolic effect of ecdysterone is based on a mechanism different from other “traditional” 
AAS, which is in line with activation of ERbeta instead than AR receptors. 
The optimization of the extraction procedure showed that either extraction using SPE (Oasis 
HLB cartridges) or dilution and injection of post-administration urine sample are the most 
suitable methods for sample pretreatment. Anyway, since no differences in abundance of 
ecdysterone were found after enzymatic hydrolysis (with β-glucuronidase or β-
glucuronidase/ arylsulfatase) and neither ecdysterone glucuronide nor ecdysterone sulfate 
were detected in the non-hydrolyzed samples, we can exclude that ecdysterone undergoes 
phase II metabolism in the body, at least by conjugation with glucuronic or sulfuric acid. On 
the other hand, thanks to the successful synthesis of 14-desoxy-ecdysterone, this 
metabolite has been confirmed in post administration urines by comparison of retention time 
and relative mass spectra of the reference material, using LC-QTOF-MS in MS1 mode, with 
MS/MS spectra used for confirmation, after simply diluting and injecting the urine samples. 
The 20-desoxy- and 25-desoxy-ecdysterone, were excluded as possible metabolites by 
comparison with the corresponding standard references.  
Through this study, the parent compound ecdysterone, which is the most abundant analyte 
in the post administration urines, and its 14-desoxy metabolite, can be easily integrated in 
the current initial testing procedures for monitoring the prevalence in elite sport. Even more, 
through the evaluation of the excretion profiles of ecdysterone and its desoxy metabolite, it 
is possible to detect the parent compound ecdysterone for more than 2 days using LC-
QTOF-MS with no pre-concentration. The maximum concentration was reached in the urine 
collected at 2.0-3.5 hours after administration. The desoxy metabolite, instead, has a 
shorter detection window (2 days) with a maximum concentration in the 7.25-9 hour urine. 
This study showed that targeting the parent compound can be performed either with LC-
MS/MS by dilute-and-inject or alternatively using GC-MS after derivatization with 
trimethyliodsilane (TMIS). Due to the impossibility of using mass spectrometry alone to 
provide reliable assignment of the exact isomer of metabolites, the synthesis of additional 
reference material is requested for the correct identification of possible metabolites. 
In the future, in-vitro experiments should be evaluated in order to investigate metabolic 
pathways of ecdysterone and controlled administration trial in humans (including men and 
women) should be performed, to elucidate its metabolism and differences in gender. 
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In conclusion, due to its effective potential to enhance performance in sport, it is suggested 
to include ecdysterone in the S1.2 “other anabolic agent” list of prohibited substances and 
methods. Recently, ecdysterone has been included in the 2020 Monitoring Program [85] 
under the session “Anabolic agents”, In-and Out-of-Competition. Based on the investigation 
reported herein, methods to trace back an administration of ecdysterone in urine and serum 
are made available together with a method for the unambiguous identification and 
quantitation of ecdysterone in natural preparations. 
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6 Summary 
The focus of this study is ecdysterone, a steroid hormone naturally occurring in plants and 
invertebrates [19, 20]. Ecdysterone is contained in a wide range of dietary supplements 
available on internet, and there are many rumors on ecdysterone misuse by athletes. 
Ecdysterone is not yet included in the list of prohibited substances and methods in sports, 
even if previous studies reported growth promoting and anabolic effects of ecdysterone in 
various animal species and in humans [28-45], mediated by its interaction with ERbeta [29, 
46, 47]. With the exception of few studies [32, 119, 120], the evaluation of the use of 
ecdysterone supplementation to improve performances and study on its metabolism, have 
not yet been extensively investigated in humans. As part of this project, an intervention 
study of strength training of 46 healthy males has been carried out. The evaluation of a 
long-term administration of an ecdysterone containing dietary supplement has been made, 
with a special focus on the enhance of the performance during resistance training. Different 
doses of a supplement labelled to contain 100 mg of ecdysterone per capsule were 
administered to volunteers for ten weeks. This study included two training groups, Ec1 and 
Ec2 , which took respectively two and eight capsules per day, one non-training COG, which 
took two capsules per day (similar to Ec1), and one PLG, which was training taking a 
supplement not containing any ecdysterone. This study considered and evaluated 
anthropometrical and performance parameters after ten weeks of administration of 
ecdysterone containing supplements, and as results, reports an increase in body weight, 
muscle mass and upper body strength performances. In addition, the in-vitro study 
performed, shows a hypertrophy in C2C12 myotubes after 48 hour of treatment with 
supplement extract. The liver and kidney toxicity of ecdysterone is excluded by evaluation 
of specific biomarker in serum; changes in the serum concentration of endocrine hormones 
IGF-1 and T4 are observed. Even if further investigations will be needed, also considering 
other endocrine hormones, it seems that ecdysterone can antagonize the decrease in IGF-
1 levels and that intensive training may have an influence on T4. In serum samples, a dose 
dependent increase of ecdysterone is reported after a successful development and 
validation of an UHPLC-MS/MS method. After a complete anti-doping screening, no other 
prohibited substance has been detected in the post administration urines as well as in the 
supplements administered to volunteers, demonstrating that the obtained effects on 
performance are resulting from consumption of ecdysterone. Following evaluation of the 
steroidal profile, it is proved that ecdysterone cannot be detected by changes in parameters 
of the steroidal module. This suggests that the anabolic effect of ecdysterone is based on 
a different mechanism than other AAS. From the analysis of the supplement administered 
to volunteers results that only 6% of the labelled content of ecdysterone is present in the 
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supplement and there is no presence of other performance enhancing substances. After a 
single dose administration of pure ecdysterone, its metabolism has been preliminary 
evaluated. Ecdysterone does not undergo phase II metabolism by conjugation with 
glucuronic or sulfuric acid. The 14-desoxy-metabolite is identified in post-administration 
urines through analysis with LC-QTOF-MS and confirmed by comparison with the MS/MS 
spectra of the synthetized 14-desoxy-ecdysterone. As result, ecdysterone (the most 
abundant analyte detected in post-administration urines) and the 14-desoxy-ecdysterone 
can be used for initial testing procedures for monitoring of ecdysterone administration in 
sport. Even more, excretion profiles of both ecdysterone and the 14-desoxy metabolite have 
been delineated. Finally, since the use of dietary supplements is increasing and their quality 
is not always guaranteed to consumers, due to the lack of adequate and uniform 
regulations, an UHPLC-MS/MS method for quantitation of 12 supplements labelled to 
contain ecdysterone has been developed and validated. The results report that in the 67% 
of the analyzed supplements, the labelled content of ecdysterone is highly inaccurate and, 
for some of them, the composition on the label is imprecise.  
Thanks to this project, the WADA has included ecdysterone in the 2020 Monitoring 
Program. Methods to trace back an administration of ecdysterone in urine and serum are 
made available together with a method for the unambiguous identification and quantitation 
of ecdysterone in natural preparations. 
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7 Zusammenfassung 
Der Fokus dieser Studie ist Ecdysteron, ein Steroidhormon, welches natürlich in Pflanzen 
und Wirbellosen vorkommt [19, 20]. Ecdysteron ist in vielen über das Internet erhältlichen 
Nahrungsergänzungsmitteln enthalten und es gibt viele Spekulationen über den 
Missbrauch von Ecdysteron bei Sportlern. Ecdysteron ist noch nicht in die Liste der 
verbotenen Substanzen und Methoden im Sport aufgenommen, selbst wenn frühere 
Studien Wachstumsförderung und anabole Effekte von Ecdysteron bei vielen Tierarten und 
beim Menschen nachweisen konnten [28-45]. Dies geschieht hauptsächlich über die 
Interaktion mit ERbeta [29, 46, 47]. Mit Ausnahme weniger Studien [32, 119, 120] ist der 
Einsatz von Ecdysteron-Supplementierung zur Leistungssteigerung und der Stoffwechsel 
beim Menschen noch nicht umfassend untersucht worden. Als Teil dieser Arbeit wurde eine 
Interventionsstudie zum Krafttraining mit 46 gesunden Männern durchgeführt. Es wurde der 
Langzeitgebrauch von einem ecdysteronhaltigen Nahrungsergänzungsmittel mit 
besonderem Fokus auf die Leistungssteigerung während des Krafttrainings untersucht. 
Unterschiedliche Dosen eines Nahrungsergänzungsmittels, welches laut Deklaration 
100 mg Ecdysteron pro Kapsel enthalten sollte, wurden über einen Zeitraum von zehn 
Wochen von den Probanden eingenommen. Die Studie beinhaltete insgesamt vier 
Gruppen: zwei Trainingsgruppen, Ec1 und Ec2, nahmen jeweils zwei bzw. acht Kapseln 
pro Tag ein, eine nicht-trainierende COG, welche zwei Kapseln pro Tag einnahm 
(vergleichbar mit Gruppe Ec1) und eine PLG, welche bei Einnahme eines 
Nahrungsergänzungsmittels ohne Ecdysteron trainierte. Diese Studie betrachtete und 
beurteilte anthropometrische und Leistungsparameter nach zehn Wochen der Einnahme 
von ecdysteronhaltigen Nahrungsergänzungsmitteln und stellte als Ergebnis eine Zunahme 
des Körpergewichts, der Muskelmasse und der Oberkörperkraft fest. Darüber hinaus zeigt 
die durchgeführte in-vitro Studie eine Hypertrophie in C2C12 Myotuben nach 48 Stunden 
der Behandlung mit Nahrungsergänzungsmittel-Extrakt. Die Leber- und Nierentoxizität von 
Ecdysteron wird durch den Nachweis von spezifischen Biomarkern im Serum 
ausgeschlossen; Veränderungen in den Serumkonzentrationen der endokrinen Hormone 
IGF-1 und T-4 wurden beobachtet. Auch wenn noch weitere Untersuchungen unter 
Berücksichtigung anderer endokriner Hormone erforderlich sein sollten, kann festgestellt 
werden, dass Ecdysteron der IGF-1 Abnahme entgegenwirken kann und intensives 
Training einen Einfluss auf T4 haben kann. Nach erfolgreicher Entwicklung und Validierung 
einer UHPLC-MS/MS-Methode konnte eine dosisabhängige Zunahme von Ecdysteron in 
Serumproben nachgewiesen werden. Nach einem kompletten Anti-Doping Screening 
konnten weder in den postadministrativen Urinproben noch in den verabreichten 
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Nahrungsergänzungsmitteln verbotene Substanzen nachgewiesen werden. Dies zeigt, 
dass die beobachteten Effekte der Leistungssteigerung von der Ecdysteroneinnahme 
herrühren. Nach Beurteilung des Steroidprofils konnte gezeigt werden, dass Ecdysteron 
nicht über Veränderungen von Parametern des Steroidmoduls nachgewiesen werden kann. 
Das deutet darauf hin, dass der anabole Effekt von Ecdysteron auf einem Mechanismus 
beruht, der von anderen AAS abweicht. Die Analyse der verabreichten 
Nahrungsergänzungsmittel zeigte, dass nur 6 % der deklarierten Menge an Ecdysteron 
tatsächlich in den Kapseln vorhanden war und dass keine weiteren leistungssteigernden 
Substanzen zugesetzt wurden. Der Metabolismus von Ecdysteron wurde nach einmaliger 
Applikation der Reinsubstanz vorläufig untersucht. Ecdysteron unterzieht sich keinem 
Phase II Metabolismus durch Konjugation mit Glucuron- oder Schwefelsäure. Der 
14-Desoxy-Metabolit wurde in Postadministrationsurinen mittels Analyse an einem LC-
QTOF-MS Instrument detektiert und durch den Vergleich mit dem MS/MS Spektrum der
synthetisierten Substanz bestätigt. Folglich können Ecdysteron, der am häufigsten in
postadministrativen Urinen detektierte Analyt und 14-Desoxy-Ecdysteron für erste
Testverfahren für die Überwachung des Ecdysterongebrauchs im Sport genutzt werden.
Des Weiteren wurden Ausscheidungsprofile von Ecdysteron und 14-Desoxy-Ecdystreon
erstellt. Da die Verwendung von Nahrungsergänzungsmitteln zunimmt und ihre Qualität den
Verbrauchern mangels angemessener und einheitlicher Vorschriften nicht immer garantiert
ist, wurde schließlich eine UHPLC-MS/MS-Methode zur Quantifizierung von 12 mit
Ecdysteron markierten Nahrungsergänzungsmitteln entwickelt und validiert. Es wurde
herausgefunden, dass in 67 % der analysierten Nahrungsergänzungsmittel der
gekennzeichnete Gehalt an Ecdysteron sehr ungenau ist und für einige von ihnen die
Zusammensetzung unpräzise deklariert ist. Infolge dieser Arbeit hat die WADA Ecdysteron
in das Monitoring Programm 2020 aufgenommen. Methoden zur Rückverfolgung einer
Ecdysteroneinnahme im Urin und im Serum wurden zusammen mit einer Methode zur
eindeutigen Identifikation und Quantifikation von Ecdysteron in natürlichen Zubereitungen
bereitgestellt.
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